Non-invasive brain and spinal stimulation for pain and related symptoms in multiple sclerosis: a systematic review by Zucchella, Chiara et al.
SYSTEMATIC REVIEW
published: 20 November 2020
doi: 10.3389/fnins.2020.547069
Frontiers in Neuroscience | www.frontiersin.org 1 November 2020 | Volume 14 | Article 547069
Edited by:
Marco Solmi,
University of Padua, Italy
Reviewed by:
Enrico Collantoni,
University of Padua, Italy
Francesco Monaco,





†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Perception Science,
a section of the journal
Frontiers in Neuroscience
Received: 31 March 2020
Accepted: 09 October 2020
Published: 20 November 2020
Citation:
Zucchella C, Mantovani E, De Icco R,
Tassorelli C, Sandrini G and
Tamburin S (2020) Non-invasive Brain
and Spinal Stimulation for Pain and
Related Symptoms in Multiple
Sclerosis: A Systematic Review.
Front. Neurosci. 14:547069.
doi: 10.3389/fnins.2020.547069
Non-invasive Brain and Spinal
Stimulation for Pain and Related
Symptoms in Multiple Sclerosis: A
Systematic Review
Chiara Zucchella 1†, Elisa Mantovani 2†, Roberto De Icco 3,4, Cristina Tassorelli 3,4,
Giorgio Sandrini 3,4 and Stefano Tamburin 1,2*
1 Section of Neurology, Department of Neurosciences, Verona University Hospital, Verona, Italy, 2Department of
Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy, 3Neurorehabilitation Unit, IRCCS
Mondino Foundation, Pavia, Italy, 4Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
Background: Neuropathic and nociceptive pain frequently affect patients with multiple
sclerosis (MS), with a prevalence close to 90% and significant impact on general health
and quality of life. Pharmacological strategies are widely used to treat pain in MS,
but their effectiveness and side-effects are controversial. Among non-pharmacological
treatments for pain, non-invasive brain and spinal stimulation (NIBSS) has shown
promising preliminary results in MS.
Objective: Systematic review to investigate the effect of NIBSS for the management of
pain in MS.
Methods: A literature search using Pubmed, Science Direct and Web of Science was
conducted from databases inception to February 21, 2020 for studies assessing the
analgesic effect of NIBSS on pain in MS.
Results: A total of 279 records were title- and abstract-screened, nine were assessed
for full text and included. The NIBSS techniques explored were transcranial direct current
stimulation (N = 5), transcranial magnetic stimulation (N = 2), transcranial random noise
stimulation (N =1), transcutaneous spinal direct current stimulation (N = 1). The targets
were the primary motor cortex (M1;N= 4), the left dorsolateral pre-frontal cortex (DLPFC;
N = 3), the spinal cord (N = 1), unspecified brain target (N = 1). The study designs
were randomized (N = 7), open label (N = 1), single case report (N = 1). Despite the
differences in study design, target and NIBSS technique that impeded a meta-analysis,
all the studies converge in showing a significant improvement of pain after active NIBSS
with less consistent effects on other symptoms of the pain-related cluster (depression,
fatigue, cognition) and quality of life.
Conclusions: Excitatory NIBSS over M1, left DLPFC and spinal cord appear to
be the most effective protocols for pain in MS. Open questions include the use of
neurophysiological or neuroimaging surrogate outcome measures, the stratification of
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patients according to the clinical profiles and underlying pathogenetic mechanisms
and the combination of NIBSS to pharmacological treatment, neurorehabilitation, or
psychotherapy to improve the clinical effect. The duration of the effect to NIBSS and the
feasibility and efficacy of telemedicine NIBSS protocols are other open key questions.
Keywords: depression, fatigue, multiple sclerosis, non-invasive brain stimulation (NIBS), non-invasive spinal
stimulation, pain, systematic review
INTRODUCTION
Pain is common in patients with multiple sclerosis (MS;
O’Connor et al., 2008) and has a significant burden on general
and psychological health, quality of life (QoL), work and social
role (Kalia and O’Connor, 2005; Foley et al., 2013). Pain was
reported in 29–86% of MS patients, such a wide range being
due to different diagnostic criteria and assessment methods,
heterogeneity of the samples, and different disease stages span
when pain was assessed (Nurmikko et al., 2010; Thompson et al.,
2010; Foley et al., 2013; Solaro et al., 2013).
MS-related pain may present with high variability in terms of
clinical presentation, severity, onset (Feinstein et al., 2015) and
may be reported at any stage of the disease including the early
ones (Solaro et al., 2004), but its prevalence increases over time
because of the disease process itself, MS-related complications
and aging (Khan et al., 2013).
The most common types of pain in MS are classified
as nociceptive or neuropathic pain (Magrinelli et al., 2013).
Nociceptive pain is a physiological response secondary to the
activation of nociceptors aimed to warn the brain of real or
potential tissue damage. In contrast, neuropathic pain is due
to a lesion or disease of the peripheral or central parts of the
somatosensory system (Finnerup et al., 2016). Pain associated
with MS stands amongst the most common causes of chronic
neuropathic pain (Scholz et al., 2019).
Nociceptive pain in MS patients includes (a) musculoskeletal
system, which is often related to abnormal or forced posture,
(b) headache, which may predate or be unrelated to MS, (c)
post-traumatic pain, and (d) pain secondary to treatment, e.g.,
painful pathological fractures secondary to long-term steroid use
and immobilization causing osteoporosis (Solaro et al., 2018).
MS patients may experience both pain and spasticity, and pain
secondary to spasticity or painful tonic spasms is a subtype
of nociceptive pain frequently reported in MS (Solaro et al.,
2018). Among primary headaches, migraine was reported to be
three times more frequent in MS patients than in the general
population, to carry a considerable disability, and to be associated
with a more symptomatic course and an increased contrast
enhancing lesion activity compared to MS patients without
headache (Kister et al., 2010; Graziano et al., 2015).
Central neuropathic pain in MS includes (a) ongoing
neuropathic pain of limbs, (b) Lhermitte’s phenomenon, (c)
trigeminal neuralgia, and (d) pain associated with optic neuritis,
all of which are associated with inflammation and secondary
degeneration of central nervous system sensory pathways (Truini
et al., 2013; Solaro et al., 2018).
MS patients may also report, to a variable extent, psychogenic,
idiopathic or mixed pain (Truini et al., 2013). Psychogenic
pain is defined as somatoform pain associated with psychiatric
conditions (i.e., depression, or anxiety), or as pain behaviors
associated with chronic refractory pain; idiopathic pain includes
poorly understood and to some extent controversial chronic
pain conditions, such as fibromyalgia, or persistent idiopathic
facial pain, while mixed pain includes different pain types,
often difficult to separate and quantify, caused by the same
disease through different pathophysiological mechanisms
(Truini et al., 2013).
According to the neuropathic pain definition and grading
system (Finnerup et al., 2016), neuropathic pain can be separated
from nociceptive and other types of pain based on the clinical
or instrumental demonstration of a lesion or disease involving
the somatosensory system (La Cesa et al., 2015; Porro et al.,
2016), but this task may be difficult in MS patients, because of the
frequent clinical or subclinical involvement of posterior columns
of the spinal cord and/or brain somatosensory pathways.
Pain can interfere with daily functioning by reducingmobility,
working activities, and engagement in recreational activities,
and may cause a consistent impairment of participation in
home, social, and other activities (Ehde et al., 2003; Svendsen
et al., 2003, 2005; Kalia and O’Connor, 2005; Grasso et al.,
2008; Gromisch et al., 2019). MS is one of the most common
causes of neurological disability in young adults, and MS-related
pain may impact this population of working-age patients and
represent an independent risk factor for social disadvantage
(Shahrbanian et al., 2013).
Pain is frequently associated to fatigue, depression and
cognitive complaints in MS patients (Penner et al., 2007; Trojan
et al., 2007), and these three symptoms may influence each other
(Harrison et al., 2015; Marck et al., 2017), being considered a
symptom cluster with some shared pathogenetic mechanisms
and that should be targeted together to improve patients’ QoL
(Shahrbanian et al., 2015).
Despite its high prevalence and severe burden, MS-related
pain is still an ongoing and challenging issue with no established
treatment. Pharmacological treatment of pain in MS patients
is based on guidelines derived from other clinical conditions
(Finnerup et al., 2015) and includes (a) non-steroidal anti-
inflammatory drugs for nociceptive pain, (b) anticonvulsant,
(c) antidepressants, and (d) botulinum toxin for neuropathic
pain, (e) cannabinoids, (f) muscle relaxants and (g) intrathecally
administered baclofen for pain secondary to spasticity or to
painful tonic spasms, (h) opioid analgesics for mixed pain (Solaro
et al., 2013). However, results of pharmacological approaches,
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even with complex therapeutic schemes, are often poor and
disturbing side effects, such in the case of opioids, frequently
cause the patients to drop-out (Urits et al., 2019).
The need of more effective treatments with safer profiles and
fewer adverse effects has paved the way to non-pharmacological
interventions for pain in MS (Amatya et al., 2018; Aboud and
Schuster, 2019). In this field, evidence on neuromodulation
through non-invasive brain and spinal stimulation (NIBSS) has
been published in recent years, and preliminary results appear
to be promising (Abboud et al., 2017; Iodice et al., 2017). NIBBS
techniques can be grouped into two categories, namely electrical
and magnetic stimulation, according to the differential way
of inducing their neurobiological effects. Electrical stimulation
is the application of current/voltage to two or more surface
electrodes, whereas magnetic stimulation results from a current
passing through a coil positioned on the head to generate
a magnetic field, inducing in turn an electrical field and a
current density field in the brain (Peterchev et al., 2012).
Electrical stimulation techniques include, but are not limited
to, transcranial direct current stimulation (tDCS), transcranial
alternating current stimulation, transcranial random noise
stimulation (tRNS), and transcutaneous spinal direct current
stimulation (tsDCS).
tDCS and repetitive transcranial magnetic stimulation
(rTMS) are the most widely used types of non-invasive
neuromodulation techniques.
tDCS is based on a battery-powered device connected to
two electrodes that deliver low-amplitude direct currents that
induce neuronal membrane depolarization or hyperpolarization
leading to changes in the excitability of specific brain areas
being stimulated (Nitsche and Paulus, 2000). In healthy subjects,
anodal tDCS delivered to the motor cortex causes neurons
depolarization and increased cortical excitability, while cathodal
tDCS hyperpolarizes neurons, thus reducing cortical excitability
(Nitsche and Paulus, 2000). However, the effect of tDCS polarity
on motor cortex excitability might not be generalized to other
cortices, and several factors (e.g., stimulation duration, current
intensity, tDCS setup) may affect the direction of the induced
effects (Lefaucheur et al., 2017).
tDCS induces sustained changes in cortical excitability if
applied for a sufficient period of time, (Nitsche and Paulus, 2001).
tDCS is safe and has been reported to cause only mild side effects,
e.g., skin irritation or burning sensation, especially when used
daily and/or with higher current intensity (Antal et al., 2017).
This side effect could be minimized when using saline-soaked
electrodes (Antal et al., 2017).
rTMS is delivered to the brain by a phasic electrical current
that circulates through an insulated wire coil placed over the
skull and generates a transient high-intensity magnetic field,
which propagates in space and induces a secondary current that
depolarizes neurons in targeted brain regions, finally leading
to neuroplastic changes (Paulus et al., 2013). High- and low-
frequency rTMS have short-lasting excitatory and inhibitory
effects on the motor cortex, respectively (Paulus et al., 2013),
but the effect of rTMS frequency cannot be generalized to all
cortical sites (Lefaucheur et al., 2020). Theta-burst stimulation
(TBS) is a novel modified rTMS technique that causes consistent,
long-lasting facilitatory and inhibitory effects on synaptic
transmission according to the TBS protocol used (Huang et al.,
2005). Intermittent TBS (iTBS) causes prevalent facilitation,
while continuous TBS leads to prevalent inhibition (Huang et al.,
2005). rTMS side effects are transient and include headache, scalp
discomfort and hearing disorders, more commonly after high-
frequency treatments, while epileptic seizures very seldom occur
if appropriate guidelines are applied and patients are accurately
selected (Rossi et al., 2009; Lefaucheur et al., 2020).
New NIBSS protocol have been recently introduced in the
clinical setting, including tRNS (Terney et al., 2008) and tsDCS
(Berra et al., 2019).
tRNS is a non-invasive transcranial electrical stimulation
technique that produces a random electrical oscillation spectrum
within defined thresholds, following the Gaussian curve around
an offset midpoint (Terney et al., 2008). tRNS was reported
to induce consistent excitability increases lasting 60min after
stimulation when applied to the primary motor cortex (M1), with
higher frequencies (100–640Hz) being responsible for generating
this hyperexcitability probably through repeated opening of
sodium channels. tRNS was found to have similar effects than
tDCS without the constraint of current flow direction sensitivity
characteristic of the latter (Terney et al., 2008; Palm et al., 2016).
Anodal tsDCS may represent a potentially self-administered
NIBSS technique in those clinical conditions that are
characterized by changes in spinal cord interneurons, and
was found to inhibit nociceptive specific responses, such as the
nociceptive withdrawal reflex (NWR; Cogiamanian et al., 2011)
and the NWR temporal summation threshold (TST; Perrotta
et al., 2016), which may contribute to the pathogenesis of pain in
MS (Berra et al., 2019).
Very recent evidence-based guidelines indicated level A
evidence (definite efficacy) for high-frequency rTMS of M1
contralateral to the painful side for neuropathic pain and level B
evidence (probable efficacy) for high-frequency rTMS of the left
M1 or DLPFC for improving quality of life or pain, respectively,
in fibromyalgia (Lefaucheur et al., 2020). Despite the evidence of
the efficacy of high frequency rTMS for the treatment of some
types of pain, NIBSS is not routinely used in patients with MS
and pain. The aim of this systematic review is to collect and report
data on the role of NIBSS for themanagement ofMS-related pain.
METHODS
This systematic review was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) recommendations (Liberati et al., 2009; Moher et al.,
2015).
Eligibility Criteria
Studies assessing the effect of NIBSS on MS-related neuropathic
and/or nociceptive pain as primary or secondary outcome were
considered eligible for this systematic review. Both controlled
and exploratory studies were eligible and included and no
restrictions were placed on the publication date of the studies.
We excluded reviews, commentaries, abstracts, conference
papers, and studies on animal models or healthy subjects.
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Studies exploring NIBSS without therapeutic goals, e.g., aiming
to assess neurophysiological measures to explore MS-related
pathophysiology were also excluded. We also excluded studies
that explored the effect of NIBSS on other MS outcomes (e.g.,
fatigue, motor function, spasticity, sensory function, bladder
function, cognition) but did not include pain.
Outcomes of interest were pain measured with clinically
validated tools (e.g., Visual Analog Scale, Numerical Rating Scale,
Short FormMcGill PainQuestionnaire; Brief Pain Inventory) and
other MS symptoms related or secondary to pain (e.g., fatigue,
spasticity, psychosocial outcomes, QoL).
According to the PICOS model, the Participants were MS
patients, the Intervention was NIBSS, the Comparison was sham
NIBSS, other pain treatment or no treatment, the Outcome was
pain either neuropathic or nociceptive, the Study design was
controlled and exploratory studies.
Search Strategy
The Pubmed, Science Direct and Web of Science databases were
searched for peer-reviewed papers exploring the therapeutic role
of NIBSS for MS-related pain, published from database inception
until February 21, 2020. Only studies written in English were
considered. Different search strings were used according to the
maximum number of Boolean operators that are allowed in each
of the selected databases.
The search string for Pubmed and Web of Science was: (pain
OR chronic pain OR pain management OR pain intractable
OR pain measurement OR pain threshold OR nociceptors OR
neuropathic pain OR neuralgia) AND (multiple sclerosis OR
demyelinating disease) AND (transcranial magnetic stimulation
OR TMS OR r-TMS OR theta burst stimulation OR theta
burst OR TBS OR c-TBS OR i-TBS OR NIBS OR non-invasive
brain stimulation OR brain stimulation OR transcranial direct
current stimulation OR tDCS OR tES OR transcranial electrical
stimulation OR tCS OR transcranial current stimulation).
The search strategy for Science Direct database included:
(pain OR nociceptors OR neuralgia) AND (multiple sclerosis OR
demyelinating disease) AND (transcranial magnetic stimulation
OR TMS OR r-TMS OR theta burst stimulation), then (pain
OR nociceptors OR neuralgia) AND (multiple sclerosis OR
demyelinating disease) AND (theta burst OR TBS OR c-TBS
OR i-TBS), (pain OR nociceptors OR neuralgia) AND (multiple
sclerosis OR demyelinating disease) AND (NIBS OR non-
invasive brain stimulation OR brain stimulation OR transcranial
direct current stimulation), and (pain OR nociceptors OR
neuralgia) AND (multiple sclerosis OR demyelinating disease)
AND (tDCS OR tES OR transcranial electrical stimulation OR
transcranial current stimulation).
Study Selection
Search results were uploaded to Rayyan software, a web-based
app to facilitate collaborations among reviewers during the study
selection phase (Ouzzani et al., 2016). Two authors (CZ, EM)
independently screened titles and abstracts. The reference lists
of relevant papers were manually checked to identify additional
significant studies potentially missed in the databases search.
Any disagreement was planned to be solved by consensus or
consulting a third reviewer (ST).
Data Collection Procedure
Two authors (CZ, EM) independently extracted the following
data from the included papers: study design (i.e., randomized,
cross-over, parallel, open label, single arm trials), type of MS,
sample size, gender and age of included patients, type of pain
targeted by the NIBSS intervention, type of NIBSS applied,
targeted central nervous system area, NIBSS protocol features,
primary and secondary outcome measures, follow-up duration,
side effects, and results.
Risk of Bias Assessment
Risk of bias was assessed independently by two authors (CZ
and EM) using the revised tool for Risk of Bias in randomized
trials (RoB 2.0), which consists of five domains and an overall
judgement (Sterne et al., 2019). The five domains are: (1) bias
arising from the randomization process; (2) bias due to deviations
from the intended interventions; (3) bias due to missing outcome
data; (4) bias inmeasurement of the outcome; (5) bias in selection
of the reported result (Sterne et al., 2019).
Any disagreement was planned to be solved via consensus or
by consulting a third author (ST). Risk of bias was classified as
“low,” “some concerns” “high.”
Data Analysis
A systematic and descriptive analysis of the results was provided
with information presented in the text and Tables 1–3 to
summarize and explain the characteristics and findings of
the included studies. A meta-analysis was not feasible due
to the small number of studies and subjects, as well as to
the methodological, clinical and statistical heterogeneity of the
included studies.
RESULTS
Identification and Selection of the Studies
A total of 279 records were identified. After removal of duplicates,
186 papers were screened through title and abstract and 9 papers
were obtained for full-text screening. The reference lists of
relevant papers were inspected for additional studies potentially
missed in the databases search, but no significant papers were
further added. Two authors (CZ, EM) independently evaluated
the 9 papers selected for the full-text examination. Disagreement
was solved by consensus between the two reviewers, therefore the
advice of a third reviewer (ST) was not required.
Nine studies fulfilled the criteria and were included in the
systematic review (Figure 1).
Description of the Included Studies
The included papers evaluated the efficacy of NIBSS on
neuropathic or nociceptive pain in MS patients. Studies were
grouped according to the NIBSS technique (i.e., tDCS, rTMS,
tRNS, tsDCS).
























TABLE 1 | Overview of the tDCS studies included in the review.
Study Patients features tDCS features Findings
Ref Design MS type Sample size
(gender, age)










RR 19 (W: 11, M: 8;
age 44.8 ± 27.5)























16 (W: 13, M: 3;
age 48.9 ± 10.0)
NP Left DLPFC Three daily sessions,
2mA, 20min; active-
sham 3 weeks washout;

















Feasibility pilot SP: 12, RR:
6, PP: 2
(EDSS: 1–8)
20 (W: 17, M: 3;
age 51 ± 9.25)









































RR 6 (W: 3, M: 3;
age 46.7 ± 14.1)












None None Pain, fatigability and
fatigue improved to
active tDCS
ANT, Attention Network Test; ANT-I, Attention Network Test-Interaction; BDI, Beck Depression Inventory; BPI, Brief Pain Inventory; DLPFC, dorsolateral pre-frontal cortex; EDSS, Expanded Disability Status Scale; [18F] FDG-PET, [18F]
fluorodeoxyglucose positron emission tomography; FSS, Fatigue Severity Scale; HADS, 14-item Hospital Anxiety and Depression Scale; M, men; mA, milliampere; MFIS, Multidimensional Fatigue Inventory Score; MPQ-SF, McGill pain
questionnaire short form; MS, multiple sclerosis; MSQOL-54, Multiple Sclerosis Quality of Life-54 scale; M1, primary motor cortex; NP, neuropathic pain; NPSI, Neuropathic Pain Symptom Inventory; NS, not specified; PANAS, Positive
and Negative Affect Schedule; PP, primary progressive; PROMIS, Patient Reported Outcomes Measurement Information System; QoL, quality of life; Ref, reference; RR, relapsing remitting; SP, secondary progressive; tDCS, transcranial














































































TABLE 2 | Overview of the rTMS studies included in the review.
Study Patients features rTMS features Findings
Ref Design MS type Sample size
(gender, age)







Seada et al. (2013) Randomized,
parallel (control
group: LLT)
NS 30 (age 56.4 ±
6.6)












Korzhova et al. (2019) Randomized,
parallel, single blind
sham-controlled




M1 Ten sessions for 5 days for
2 weeks; HF rTMS (20Hz,



















CMAP, compound muscle action potential; HF, high frequency; Hz, hertz; iTBS, intermittent theta-burst stimulation; LLT, low-level laser therapy; M, men; mA, milliampere; MAS, Modified Ashworth Scale; MFIS, Multidimensional Fatigue
Inventory Score; MS, multiple sclerosis; M1, primary motor cortex; NAS, numerical analog scale; NRS, numerical rating scale; NS, not specified; Ref, reference; rTMS, repetitive transcranial magnetic stimulation; SESS, Subjective
Evaluating Spasticity Scale; SP, secondary progressive; tDCS, transcranial direct current stimulation; TNP, trigeminal neuropathy; W, women.
TABLE 3 | Overview of the other NIBSS studies included in the review.
Study Patients features NIBSS features Findings
Ref Design MS type Sample size
(gender, age)













16 (W: 3, M: 13;
age 47.4 ± 8.9)
NP Left DLPFC tRNS: 3 consecutive days,















Berra et al. (2019) Pilot randomized,
parallel, double-blind
sham-controlled
SP: 24, PP: 5,
RR: 4 (EDSS:
5.9 ± 1.3)
33 (W: 25, M: 8;
age: real 57.6 ±
9.1, sham: 54.0
± 7.8)
NP Spinal cord tsDCS: 10 sessions in 2
weeks, 2mA, 20min;







NWR, NWR TST 1 month None NPSI significantly
reduced to real
tsDCS with effect





ANT, Attention Network Test; AS, Ashworth scale; BPI, Brief Pain Inventory; DLPFC, dorsolateral pre-frontal cortex; EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; HADS, 14-item Hospital Anxiety and Depression
Scale; M, men; mA, milliampere; MFIS, Multidimensional Fatigue Inventory Score; MS, multiple sclerosis; NIBSS, non-invasive brain and spinal stimulation; NP, neuropathic pain; NPSI, Neuropathic Pain Symptom Inventory; NWR,
nociceptive withdrawal reflex; PP, primary progressive; PREPS, pain related evoked potentials; Ref, reference; RR, relapsing remitting; SP, secondary progressive; tRNS, transcranial random noise stimulation; tsDCS, transcutaneous
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tDCS Studies
We found five studies that explored tDCS for the treatment of
pain in MS (Mori et al., 2010; Ayache et al., 2016; Kasschau et al.,
2016; Rudroff et al., 2019; Workman et al., 2020).
Mori et al. (2010) investigated whether anodal tDCS may be
effective in reducing central drug-resistant chronic neuropathic
pain in MS with a randomized, parallel, double blind, sham-
controlled study. Nineteen patients with relapsing-remitting MS
received a 5 day treatment with sham or real tDCS over M1
contralateral to the painful body region. Real tDCS resulted
in significant reduction of pain and improvement of QoL in
comparison to sham tDCS and the effects lasted up to 3 weeks
after the stimulation period. The Authors hypothesized that pain
reduction was the result of functional plastic changes in brain
structures involved in the pathogenesis of chronic neuropathic
pain (Mori et al., 2010).
Ayache et al. (2016) reported a prospective, randomized,
cross-over, sham-controlled study to evaluate the effect of
tDCS over the DLPFC in sixteen MS patients with a history
of neuropathic pain since >3 months. The primary outcome
was pain intensity, and secondary outcomes included mood,
attention and fatigue. Patients received real or sham anodal tDCS
blocks in a random order, each consisting of tDCS sessions in
3 consecutive days, separated by a 3 week washout period. Real
tDCS yielded significant analgesic effects compared to sham, but
no effects on mood, attention, or fatigue. The Authors suggested
that analgesia might have occurred through specific modulation
of the emotional pain network by tDCS over the left DLPFC
(Ayache et al., 2016).
Since repeated tDCS sessions are needed to obtain a
therapeutic effect, but for many MS patients visiting the clinic
daily for the treatment is not feasible, Kasschau et al. (2016)
performed a pilot study to test the feasibility and safety
of a remotely supervised tDCS protocol for home delivery
using a specially designed equipment and a telemedicine
platform. Twenty MS (any subtype) patients with an extended
range of disability (Expanded Disability Status Scale = 1–
8) underwent 10 tDCS sessions over the left DLPFC, each
lasting 20min, across 2 weeks. Nineteen of them (95%)
completed at least eight sessions, meeting the compliance
criteria, while 17 (85%) completed the full 10 study sessions.
Improvement of all secondary clinical outcomes (cognitive
measures, pain, fatigue, mood) was reported. Despite the
limitations of the study, i.e., lack of a control group, and
patient economic compensation that might have increased the
attendance, this telemedicine tDCS protocol suggests that access
to tDCS can be expanded in MS patients (Kasschau et al.,
2016).
Rudroff et al. (2019) reported a 52 year old man with a 13
year history of relapsing-remitting MS, moderate disability and
central neuropathic pain, treated with anodal tDCS (20min,
5 consecutive days) over the left M1. Pain scores improved
andmetabolism, assessed with [18F] fluorodeoxyglucose positron
emission tomography, increased in both thalami, suggesting at a
very preliminary stage that tDCS may induce functional changes
in brain structures critical in the pathogenesis of neuropathic
pain (Rudroff et al., 2019).
Workman et al. (2020) reported the results of a double
blind, sham-controlled, randomized cross-over pilot study to
investigate whether tDCS may improve the MS symptom
cluster of pain, fatigue and depression. Six moderately disabled
MS patients underwent two randomly ordered blocks of
stimulation (real or sham tDCS), each block composed of five
daily 20min sessions, with the anode placed over the M1
representation of the more-affected leg and the cathode over
the contralateral supraorbit. Real tDCS improved performance
fatigability, perceived fatigue and pain but not depression in
comparison to sham (Workman et al., 2020).
rTMS Studies
We found two studies that explored rTMS in MS with
pain as primary (Seada et al., 2013) or secondary outcome
(Korzhova et al., 2019).
Seada et al. (2013) reported a randomized, parallel study
that compared rTMS and low-level laser therapy for trigeminal
neuralgia in thirty MS patients. Patients were randomly divided
into rTMS group (age 46.6 ± 9.6) who received rTMS (10Hz,
50mA, 20min) with the coil placed tangentially over the head of
the patient contralateral to trigeminal pain and the laser group
(age 48.8 ± 6.3) who received low-level laser therapy (15 mW
helium-neon laser, 830A wave length, 150–170 mw/cm2 laser
beam density, 10min). Both groups reported improvements, but
no statistical comparison between the two groups was performed
(Seada et al., 2013). Indeed, some methodological issues should
be noted, such as poor description of rTMS targeting, absence
of a sham group, unclear significance of outcome measures and
some poorly reported data (e.g., the overall mean age was 56.4 ±
6.6 that is in contrast with the age of the two groups, see above).
Korzhova et al. (2019) performed a parallel, randomized
controlled trial to compare the effects of two rTMS protocols,
i.e., high frequency (20Hz) and iTBS in comparison to a sham
group on the level of spasticity (primary outcome) and associated
symptoms, including pain that was a secondary outcome, in
thirty-four secondary progressive MS patients. All patients
underwent real (high frequency rTMS: twelve patients, iTBS:
twelve patients) or sham rTMS (ten patients) once a day for
5 consecutive days for 2 weeks. Concurrently with rTMS, all
patients received a course of 10 physical therapy sessions. Both
high frequency rTMS and iTBS significantly reduced spasticity
with some evidence favoring a longer-lasting effect of iTBS and a
reduction of pain and fatigue to high frequency rTMS (Korzhova
et al., 2019).
Other NIBSS Studies
We found two studies (Table 3), one dealing with tRNS (Palm
et al., 2016) and one with tsDCS (Berra et al., 2019).
Palm et al. (2016) explored the effect of tRNS over the
left DLPFC on affective symptoms, attention, fatigue, and
pain by exploring pain perception and attentional resources
in a prospective randomized, cross-over, sham-controlled study
of sixteen MS patients with neuropathic pain. Each patient
randomly received two tRNS blocks (i.e., real, sham), each
consisting of three consecutive 20min daily sessions, separated
by a 3 week washout interval. All patients were evaluated for
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FIGURE 1 | PRISMA diagram of the study (www.prisma-statement.org).
pain, attention and mood and underwent a neurophysiological
evaluation using pain related evoked potentials. Compared to
sham, real tRNS showed a trend toward decreased N2-P2
amplitude of pain related evoked potentials and improvement of
pain ratings, while attention performance and mood scales did
not change (Palm et al., 2016).
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FIGURE 2 | Assessment of the risk of bias for controlled studies included in the systematic review according to the RoB 2.0 tool.
Berra et al. (2019) explored whether anodal tsDCS could
represent an effective, safe and well-tolerated treatment for
neuropathic pain in MS in a double-blind sham-controlled,
parallel design study involving thirty-three patients. Real tsDCS
resulted in a significant improvement in neuropathic pain
scores at the end of treatment that persisted 1 month later,
but no changes in spasticity and fatigue. In a subgroup
of patients, who underwent NWR and NWR TST, a non-
significant trend toward an inhibition of NWR responses to
real tsDCS was found, suggesting the effect of tsDCS was
related to modulation of spinal nociception (Berra et al.,
2019).
Risk of Bias Assessment
Only controlled studies with samples of at least ten patients (Mori
et al., 2010; Seada et al., 2013; Ayache et al., 2016; Palm et al., 2016;
Berra et al., 2019; Korzhova et al., 2019) were assessed for the risk
of bias according to the RoB 2.0 tool, which yielded an overall
high risk for all of them (Figure 2).
DISCUSSION
The present systematic review, which was aimed to collect and
report evidence on the role of NIBSS for the management of
MS-related pain, yielded nine studies, of whom five on tDCS
(Mori et al., 2010; Ayache et al., 2016; Kasschau et al., 2016;
Rudroff et al., 2019; Workman et al., 2020), two on rTMS (Seada
et al., 2013; Korzhova et al., 2019), one on tRNS (Palm et al.,
2016), and one on tsDCS (Berra et al., 2019).
Four studies targeted M1, all of them using excitatory
protocols, i.e., anodal tDCS in three of them (Mori et al., 2010;
Rudroff et al., 2019; Workman et al., 2020), and high-frequency
rTMS in another one (Korzhova et al., 2019), with the targeted
side being the one contralateral to the most affected limbs in
three of them (Mori et al., 2010; Korzhova et al., 2019; Workman
et al., 2020), and the left side in another one (Rudroff et al.,
2019). Three studies targeted the left DLPFC with excitatory
protocols, i.e., anodal tDCS in two of them (Ayache et al., 2016;
Kasschau et al., 2016) and tRNS in another one (Palm et al., 2016).
One study targeted the spinal cord with anodal tsDCS (Berra
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et al., 2019) and the brain target was not specified in one study
(Seada et al., 2013).
Seven studies had a randomized design, either double-blind
(Mori et al., 2010; Ayache et al., 2016; Palm et al., 2016; Berra
et al., 2019; Workman et al., 2020), single-blind (Korzhova et al.,
2019), or with blinding not specified (Seada et al., 2013), one
had an open design (Kasschau et al., 2016), and another one
was a single case report (Rudroff et al., 2019). Sham NIBSS was
the control group in six of the seven randomized studies (Mori
et al., 2010; Ayache et al., 2016; Palm et al., 2016; Berra et al.,
2019; Korzhova et al., 2019; Workman et al., 2020), while low-
level laser therapy was used as control condition in one study
(Seada et al., 2013).
Only three studies reported a follow-up that ranged from 4 to
12 weeks (Mori et al., 2010; Berra et al., 2019; Korzhova et al.,
2019).
Apart from the single case report, the sample size ranged from
6 to 34 with a total of 175 patients (women: 92, men: 53; gender
not specified: 30) included in the nine studies we found; among
them there were 58 relapsing-remitting patients, 78 secondary
progressive patients, 9 primary progressive patients, while MS
type was not specified in 30 patients.
Pain was the primary outcome in seven of the included studies
(Mori et al., 2010; Seada et al., 2013; Ayache et al., 2016; Palm
et al., 2016; Berra et al., 2019; Rudroff et al., 2019; Workman
et al., 2020) and secondary outcome in the other two studies, one
being on feasibility of a telemedicine tDCS protocol (Kasschau
et al., 2016), and the other one having spasticity as the primary
outcome (Korzhova et al., 2019). The type of MS-related pain
addressed in the study, either as primary or secondary outcome
measures was neuropathic pain in seven studies (Mori et al., 2010;
Seada et al., 2013; Ayache et al., 2016; Palm et al., 2016; Berra
et al., 2019; Rudroff et al., 2019; Workman et al., 2020), more
specifically central neuropathic pain in one of them (Mori et al.,
2010) and trigeminal neuralgia in another one (Seada et al., 2013),
while pain type was not specified in one study (Kasschau et al.,
2016), and another study was focused on spasticity-related pain
(Korzhova et al., 2019).
One or more of the other symptoms belonging to the
symptoms cluster associated with pain in MS, i.e., fatigue,
depression and cognitive complaints (Penner et al., 2007; Trojan
et al., 2007; Harrison et al., 2015; Marck et al., 2017), and QoL
were assessed as primary or secondary outcomes in six studies
(Mori et al., 2010; Ayache et al., 2016; Kasschau et al., 2016; Palm
et al., 2016; Berra et al., 2019; Korzhova et al., 2019).
The variability of NIBSS techniques, central nervous system
targets, study designs including sham control and blinding,
patient populations, outcomes, and the presence of follow-up
data in a minority of the studies included did not allow a
meta-analysis of the findings. However, the results of all the
included studies converge in showing a significant improvement
in pain after active NIBSS with less consistent effects on the other
symptoms of the pain-related cluster and QoL (Mori et al., 2010;
Seada et al., 2013; Ayache et al., 2016; Kasschau et al., 2016; Palm
et al., 2016; Berra et al., 2019; Korzhova et al., 2019; Rudroff et al.,
2019; Workman et al., 2020).
Most studies used validated scales to measure pain, such as
the Visual Analog Scale, the Numerical Rating Scale, the Short
Form McGill Pain Questionnaire, the Brief Pain Inventory or
similar outcomes (Jensen and Karoly, 2001). However, despite
most of the reports addressed neuropathic pain, only one study
(Berra et al., 2019) used an outcome measure that was specific for
this type of pain, i.e., the Neuropathic Pain Symptom Inventory
(Bouhassira et al., 2004), which can be used to characterize
subgroups of neuropathic pain patients and verify whether they
respond differentially to a therapeutic intervention (Magrinelli
et al., 2013). Moreover, because of the complexity of pain
experience, and the coexistence of psychiatric and cognitive
symptoms (Chiaravalloti and De Luca, 2008), MS patients may
have difficulty in reporting their experience through a single
intensity scale (Amatya et al., 2018), but only one study used
a multidimensional pain scale, i.e., the Brief Pain Inventory
(Ayache et al., 2016).
Some studies explored the MS symptom cluster related to
pain. Depression, anxiety, mood, and affect were explored in
five studies (Mori et al., 2010; Ayache et al., 2016; Kasschau
et al., 2016; Palm et al., 2016; Workman et al., 2020), but found
to improve to NIBSS only in one of them whose design was
unblinded and open (Kasschau et al., 2016) and thus prone to
placebo effect. The absence of changes in mood outcomes in the
studies targeting the DLPFC (Ayache et al., 2016; Palm et al.,
2016), might be due to the short stimulation period, since the
effect on mood to DLPFC non-invasive stimulation is known to
be dose-dependent (Palm et al., 2016).
Fatigue was an outcome measure in six studies (Ayache
et al., 2016; Kasschau et al., 2016; Palm et al., 2016; Berra
et al., 2019; Korzhova et al., 2019; Workman et al., 2020), with
one of them performing a fatigability test with isokinetic leg
strength in addition to subjective measures (Workman et al.,
2020). Apart from the open feasibility study that found an
unspecific improvement of all outcomes (Kasschau et al., 2016),
the other studies converge in showing improvement of fatigue
and fatigability to M1 excitatory NIBSS (Korzhova et al., 2019;
Workman et al., 2020), but no effect to either targeting DLPFC
(Ayache et al., 2016; Palm et al., 2016), or the spinal cord (Berra
et al., 2019), thus suggesting thatM1may represent an interesting
target for this MS symptom, which is very bothersome, may
heavily impact on QoL and functioning, and has no established
treatment (Miller and Soundy, 2017). However, it is worth
noting that M1 reports applied 5 (Workman et al., 2020)
and 10 sessions (Korzhova et al., 2019), respectively, whereas
DLPFC studies (Ayache et al., 2016; Palm et al., 2016) applied
only 3 sessions. Studies that targeted primary fatigue in MS
documented significant effects by stimulating the DLPFC for ≥5
sessions and suggest that targeting the MS fatigue loop with 5
or more NIBSS sessions could improve the symptom (Ayache
and Chalah, 2018). In MS patients with pain, fatigue is probably
secondary to pain rather than representing primary fatigue, and
future studies should better explore this topic.
Two studies explored the effect of NIBSS on spasticity
(Berra et al., 2019; Korzhova et al., 2019) and showed
improvement of this outcome to high-frequency rTMS over
M1 (Korzhova et al., 2019), but not to anodal tsDCS (Berra
et al., 2019), offering some ground to future studies aimed to
explore excitatory NIBBS over M1 as a therapeutic strategy in
MS-related spasticity.
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Three studies explored attentional changes to left DLPFC
anodal tDCS (Ayache et al., 2016; Kasschau et al., 2016) and
tRNS (Palm et al., 2016). Only one of them (Kasschau et al.,
2016) reported improvement of attentional outcomes, but the
open design of the study, absence of blinding, and coexisting
treatment with web-based cognitive rehabilitation might have
represented potential bias factors. The left DLPFC might not
represent the best target for this cognitive domain, which is
frequently impaired in MS (Chiaravalloti and De Luca, 2008), as
anodal tDCS over the right posterior parietal cortex was reported
to be more effective on attentional measures than the left DLPFC
(Roy et al., 2015).
QoL was explored in one study only, with no evidence of
efficacy of NIBSS (Mori et al., 2010), probably because this
outcome is likely to improve in response to change of a symptom
cluster instead of a single symptom (Ehde et al., 2003; Svendsen
et al., 2003, 2005; Kalia and O’Connor, 2005).
Three studies presented follow-up data and were consistent in
showing that NIBSS effects outlasted the period of stimulation; in
particular, pain reduction lasted up to 1 month after the end of
NIBSS treatment (Mori et al., 2010; Berra et al., 2019; Korzhova
et al., 2019).
Some interesting pieces of information can be derived from
the instrumental outcomes reported in some of the studies
we collected. Rudroff et al. (2019) documented increased [18F]
fluorodeoxyglucose positron emission tomography uptake in the
thalamus after anodal tDCS and suggested that NIBSS may
modulate sensory discriminative and affective-motivational pain
pathways. However, this finding was derived from a single case
report and should be replicated in larger patient populations.
Moreover, validated and clinically reliable neuroimaging markers
of MS-related pain are still lacking (Seixas et al., 2014). Palm
et al. (2016) reported reduced amplitude of theN2-P2 component
of pain related evoked potentials. This finding might be related
to a change in cortical processing of pain, but should be taken
with care, because of the uncertainties on the fibers stimulated by
the electrode they used (Perchet et al., 2012) and the presence
of saliency and habituation effects that may represent bias
factors for the interpretation of the significance of the cortical
components to pain stimuli (Iannetti et al., 2008). Berra et al.
(2019) reported a trend for a change in NWR in parallel to
neuropathic pain improvement to tsDCS. NWR is a reliable
neurophysiological tool for the assessment of the spinal and
supraspinal mechanisms of pain processing but is sensitive to
physiological changes and to some drugs (Sandrini et al., 2005)
and not widely used in the clinical setting.
M1 and the DLPFC were the two most common NIBSS
sites for the treatment of MS-related pain in the studies we
reviewed. M1 stimulation is supposed to induce analgesic effects
trough an antidromic top-down modulation of thalamo-cortical
pathways (Nguyen et al., 2011). The DLPFC plays a pivotal role in
pain processing, as well as cognitive and emotional pain-related
behaviors, and its stimulation may act through a descending
modulation of opioidergic pathways and in the affective and
attentional aspects of pain (Seminowicz and Moayedi, 2017).
However, the underlying brain networks that mediate pain relief
to these brain targets are only partially understood, and they may
be partially disrupted in patients with MS.
In conclusion, the results of the studies included in this
systematic review indicate overall a positive effect of various
NIBSS techniques on pain and some related symptoms in
patients with MS. These results are promising but far from being
conclusive, because of the small sample size in the included
studies, the variability in NIBSS technique, targeted area, patient
population, outcomes, the absence of follow-up for many of the
studies, and the overall high risk of bias. It is worth noting that
the assessment of the risk of bias in our study differs from that in
a recent Cochrane review focused on the management of chronic
pain in MS patients (Amatya et al., 2018), because of the different
risk of bias tools used in the two studies. Excitatory NIBSS
over M1, the left DLPFC and the spinal cord appear to be the
most promising protocols to be used in future larger therapeutic
studies for MS-related pain.
Open questions include the use of neurophysiological
or neuroimaging surrogate outcome measures and the
stratification of patients according to the clinical profiles
and underlying pathogenetic mechanisms (Magrinelli et al.,
2013). Future studies should explore whether NIBSS protocols
associated to pharmacological treatment, neurorehabilitation, or
psychotherapy (Arewasikporn et al., 2018) may be more effective
than NIBSS alone on pain, related symptoms and/or QoL.
The duration of the effect to NIBSS is another key question.
Unlike other clinical conditions such as depression, there is still
no consensus regarding the treatment of MS related pain with
maintenance sessions of NIBBS beyond the normal treatment
duration. Studies on other neuropathic pain conditions suggest
that the analgesic effect to rTMS of M1 is favored by longer
session duration and serial treatment, i.e., greater number of
sessions (Lefaucheur et al., 2020). Additional studies are thus
needed to address this important question.
Regarding the last point, the use of telemedicine NIBSS
techniques may be promising (Kasschau et al., 2016), but results
are still contradictory, in that a randomized controlled pilot study
documented that patient-delivered tDCS was not effective on
mixed types of neuropathic pain in prior responders to rTMS
(O’Neill et al., 2018). Telemedicine could also lead to advantages
for designing future NIBBS clinical trials to test more appropriate
stimulation parameters, treatment duration and follow-ups. The
remote provision of NIBSS (e.g., tDCS), safely administered
at home may be an interesting option to provide accessible
maintenance protocol treatments, to explore the effects of NIBSS
in an ecological context, and to overcome the limitations of not-
portable NIBBS devices. The use of telemedicine could also be
helpful for research purposes, allowing for a better control of
experimental variables and thus increasing the reproducibility of
studies’ findings.
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